{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Number of patients with grade 3+ adverse events (AE) during therapy. (Grade 3+) = (Grade 3 + Grade 4 + Grade 5) . Grade 3: Severe and undesirable AE; Grade 4: Life threatening or disabling AE; Grade 5: Death related to AE.","groups":[{"description":"IMC-A12 + Multi-agent intensive chemotherapy regimen.","id":"OG000","title":"IMC-A12"},{"description":"Add temozolomide to vincristine/irinotecan cycles.","id":"OG001","title":"Temozolomide"}],"paramType":"NUMBER","populationDescription":"9 participants who were ineligible or did not receive treatment were excluded.","reportingStatus":"POSTED","timeFrame":"Up to 54 weeks","title":"Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0","type":"PRIMARY","unitOfMeasure":"Participants"}